Complete Regression of Hepatoblastoma after Interleukin-15– and Interleukin-21–Coexpressing CAR T-Cell Therapy
Study limitation reported by the research below: “Full safety profile, dosing details, and long-term follow-up data are not available from the provided source text alone.”